Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
4
Bullish
7
Bearish
35
Neutral
4
Bullish
7
Bearish
32
Neutral
0
Bullish
0
Bearish
3
Neutral
4
Bullish
7
Bearish
3
Neutral
4
Bullish
7
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Upcoming Result Date: Oct 26, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs).
In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid.
The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability.
Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products.
Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,08,808 Cr
Low Risk
30.4
37.0
-0.9
3.2
1,672.20
1,165.55
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1145.25 | 1,14,239 Cr | 25.43 | 4.21 | 0.09 | 18.59 | 17.35 | 8.57 | ||
1346.85 | 1,08,808 Cr | 32.34 | 3.16 | 0.97 | 11.27 | 14.95 | 7.92 | ||
1989.00 | 1,07,468 Cr | 98.53 | 20.28 | 0.10 | 16.77 | 16.14 | 10.38 | ||
2527.00 | 1,04,376 Cr | 50.48 | 6.40 | 0.04 | 11.74 | 13.13 | 7.36 | ||
1200.10 | 1,00,170 Cr | 31.47 | 2.63 | 0.67 | 11.07 | 12.54 | 5.48 | ||
1675.00 | 96,376 Cr | 25.97 | 2.54 | 0.24 | 9.25 | 11.76 | 6.34 | ||
2029.00 | 92,784 Cr | 16.71 | 4.13 | 0.89 | 23.76 | 24.88 | 14.47 | ||
| Median: 7 Co. | — | 1675.00 | 1,04,376 Cr | 31.47 | 4.13 | 0.24 | 11.74 | 14.95 | 7.92 |
Cipla Ltd (CIPLA) is currently trading at 1,346.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs). In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid. The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability. Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products. Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.
Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,165.55 and a high of ₹1,672.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Cipla Ltd has a market capitalization of approximately 1,08,808.05. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Cipla Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 30.40 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,08,808.05 Cr, Cipla Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Cipla Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Cipla Ltd is 30.40. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Cipla said it received USFDA approval for its ANDA for generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) across 100/50, 250/50 and 500/50 mcg strengths.
The upcoming result date is listed as July 23, 2026, tagged to Q1 FY2026-27 in the provided details.
The stock moved up after Cipla reported strong Q1FY26 earnings, including a 10% YoY rise in consolidated PAT to Rs 1,298 crore, and brokerages issued bullish target revisions.
Cipla shares came under pressure after the USFDA designated its manufacturing facility in Greece as Official Action Indicated (OAI), pushing the stock to an intraday low of ₹1,309 on NSE.
